{"id":616426,"date":"2022-09-15T15:38:01","date_gmt":"2022-09-15T15:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616426"},"modified":"2022-09-15T15:38:01","modified_gmt":"2022-09-15T15:38:01","slug":"intratumoral-cancer-therapies-market-is-expected-to-grow-at-a-significant-cagr-by-2032-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/intratumoral-cancer-therapies-market-is-expected-to-grow-at-a-significant-cagr-by-2032-delveinsight_616426.html","title":{"rendered":"Intratumoral Cancer Therapies Market is expected to grow at a significant CAGR by 2032 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663232572.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Intratumoral Cancer Therapies Market is expected to grow at a significant CAGR by 2032 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663232572.jpeg\" alt=\"Intratumoral Cancer Therapies Market is expected to grow at a significant CAGR by 2032 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Intratumoral Cancer Therapies Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Intratumoral Cancer Therapies market is expected to show positive growth in the forecast period (2022\u20132032) due to the increased prevalence, randomized, controlled non-crossover trials with potential benefits. Some of the main reasons for this novel therapy\u2019s insignificant revenues are its limitations, no statistically significant benefit in overall survival, and intense competition from immune checkpoint inhibitors due to their efficacy and manageable side effects.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong>Intratumoral Cancer Therapies Market Insights<\/strong>&nbsp;report includes a comprehensive understanding of current treatment practices, Intratumoral Cancer Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the&nbsp;United Kingdom,&nbsp;Italy,&nbsp;Spain,&nbsp;France, and&nbsp;Germany),&nbsp;Japan].<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/1bec6491d4fdd39c2b7b9e325e4a3d1a.jpg\" alt=\"\" \/><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the Intratumoral Cancer Therapies market report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In 2021, the total Intratumoral Cancer Therapies market size was approximately <strong>USD 93 million<\/strong> which is expected to rise during the study period (2019&ndash;2032).<\/li>\n<li>In 2021, the total Intratumoral Cancer Therapies target patient pool cases across 7MM were about <strong>469 K <\/strong>which are expected to grow during the study period, i.e., 2019&ndash;2032.<\/li>\n<li>Currently, only three intratumoral therapies are approved, namely, IMLYGIC (Talimogene laherparepvec\/T-VEC; Amgen) approved in the US, Europe and Japan in 2015, DELYTACT (teserpaturev\/G47\u2206; Daiichi Sankyo) approved in Japan in 2021 and HENSIFY (Nanobiotix) approved in European market in 2019.<\/li>\n<li>Some of the companies working in the Intratumoral Cancer Therapies market are Daiichi Sankyo,&nbsp;Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp &amp; Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals,&nbsp;Sirnaomics, Apexigen, Replimune, Merck &amp; Co (Viralytics),&nbsp;Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Intratumoral Cancer Therapies Market @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Intratumoral Cancer Therapies Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer&nbsp;therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. It is a therapeutic strategy which aims to use the tumor as its own vaccine.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">According to DelveInsight estimates, there were approximately <strong>469K<\/strong> Intratumoral Cancer Therapies targeted patient pool in the 7MM in 2021.<\/p>\n<p style=\"text-align: justify;\">Among the 7MM countries, the US had the highest incidence of Intratumoral Cancer Therapies in 2021.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The Intratumoral Cancer Therapies market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Incident cases of selected cancer types<\/li>\n<li>Target Patient Pool of Intratumoral Cancer Therapy by Cancer Types<\/li>\n<li>Total Treated cases by the line of therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Intratumoral Cancer Therapies Epidemiological Insights<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Intratumoral Cancer Therapies Pipeline Therapies and Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the Intratumoral Cancer companies working in the market are Daiichi Sankyo,&nbsp;Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp &amp; Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals,&nbsp;Sirnaomics, Apexigen, Replimune, Merck &amp; Co (Viralytics),&nbsp;Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix and others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the Intratumoral Cancer Therapies&nbsp;therapies in clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Drugs for&nbsp;Intratumoral Cancer Therapies Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the <\/strong><strong>Intratumoral Cancer Therapies<\/strong><strong> Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period:<\/strong> 2019&ndash;2032<\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key <\/strong><strong>Intratumoral Cancer Therapies<\/strong><strong> Companies: <\/strong>Daiichi Sankyo,&nbsp;Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp &amp; Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals,&nbsp;Sirnaomics, Apexigen, Replimune, Merck &amp; Co (Viralytics),&nbsp;Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix and others<\/li>\n<li><strong>Therapeutic Assessment: <\/strong>Intratumoral Cancer Therapies current marketed and emerging therapies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Intratumoral Cancer Therapies Market Access and Reimbursement<\/strong><\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about emerging Intratumoral Cancer Therapies in development @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Intratumoral Cancer Therapies Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"width: 460px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"10\">\n<tbody>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>1.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies Market&nbsp;Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>2.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies Market&nbsp;Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>3.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>4.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies Market&nbsp;Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>5.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>6.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies&nbsp;Treatment and Management<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>7.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies&nbsp;Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>8.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>9.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies&nbsp;Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>10.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>7MM&nbsp;Intratumoral Cancer Therapies&nbsp;Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>11.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies&nbsp;Market Outlook<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>12.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Potential of Current and Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>13.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>14.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies&nbsp;Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>15.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Intratumoral Cancer Therapies&nbsp;Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>16.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>17.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>18.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>19.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>20.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\" width=\"67\">\n<p>21.<\/p>\n<\/td>\n<td valign=\"bottom\" width=\"432\">\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp;Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve<strong>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=intratumoral-cancer-therapies-market-is-expected-to-grow-at-a-significant-cagr-by-2032-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=intratumoral-cancer-therapies-market-is-expected-to-grow-at-a-significant-cagr-by-2032-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intratumoral Cancer Therapies Market The Intratumoral Cancer Therapies market is expected to show positive growth in the forecast period (2022\u20132032) due to the increased prevalence, randomized, controlled non-crossover trials with potential benefits. Some of the main reasons for this novel &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/intratumoral-cancer-therapies-market-is-expected-to-grow-at-a-significant-cagr-by-2032-delveinsight_616426.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-616426","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616426"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616426\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}